Phase 3 trial results positive for new once-a-week HIV medication
A new HIV treatment taken just once per week has performed well in a Phase 3 study, proving to be as effective as current daily regimens. This medication, which merges Gilead's lenacapavir with Merck's islatravir, has the potential to be the first full oral HIV therapy administered on a weekly basis if it receives regulatory approval. Ongoing observation will be conducted to evaluate its safety profile over time.
by shortkt.com✓